Detalles de la búsqueda
1.
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Lancet
; 398(10308): 1344-1357, 2021 10 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34555333
2.
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
N Engl J Med
; 379(21): 2040-2051, 2018 11 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-30280635
3.
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Lancet Oncol
; 16(7): 763-74, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26045340
4.
Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.
J Clin Oncol
; 41(11): 1999-2006, 2023 04 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36735893
5.
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
J Clin Oncol
; 41(6): 1213-1227, 2023 02 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36327426
6.
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
Lung Cancer
; 186: 107422, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37992595
7.
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.
Nat Med
; 29(7): 1718-1727, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37429923
8.
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC.
JTO Clin Res Rep
; 4(11): 100572, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37954964
9.
Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies.
Cancers (Basel)
; 14(5)2022 Feb 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35267477
10.
Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer.
Lung Cancer
; 165: 71-81, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35093625
11.
Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer.
Ther Adv Med Oncol
; 13: 17588359211045845, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34819997
12.
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078).
Lung Cancer
; 152: 7-14, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33321441
13.
Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
Clin Lung Cancer
; 22(4): 301-312.e8, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33775558
14.
A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer.
Lung Cancer
; 146: 12-18, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32502923
15.
Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.
J Clin Oncol
; 38(3): 271-280, 2020 01 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-31751163
16.
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
J Clin Oncol
; 38(21): 2369-2379, 2020 07 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-32468956
17.
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
JAMA Oncol
; 6(5): 661-674, 2020 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32271377
18.
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.
J Thorac Oncol
; 14(5): 867-875, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30659987
19.
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.
Clin Lung Cancer
; 25(3): 266-273.e5, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38584069
20.
Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
Clin Lung Cancer
; 19(2): 130-138.e2, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29158123